Bicycle Therapeutics (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.
The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.
Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed "enhanced anti-tumor activity."
The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.
Price: 13.77, Change: -6.35, Percent Change: -31.55
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。